Phase I study of bortezomib and oxaliplatin (BOX) in solid tumors: Improved neurotoxicity (NT) profile with lower bortezomib (B) dose

Rebecca Kosloff,John J. Wright,P. Ivy,J. Escalon,B. Norwood,Benjamin Levinson,Anna C. Pavlick,A. Beric,Franco M. Muggia,Howard S. Hochster

Phase I study of bortezomib and oxaliplatin (BOX) in solid tumors: Improved neurotoxicity (NT) profile with lower bortezomib (B) dose

2006

Rebecca Kosloff
John J. Wright
P. Ivy
J. Escalon
B. Norwood
Benjamin Levinson
Anna C. Pavlick
A. Beric
Franco M. Muggia
Howard S. Hochster

12007 Background: B inhibits proteasome function and may be synergistic in causing apoptotic death with platinum agents. We were interested in combining B with OX but concerned with dose limiting (...

Keywords:

Neurotoxicity
Bortezomib
Cancer research
Oxaliplatin
Materials science
phase i study
Internal medicine
Oncology
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations